The Insurance Battle: Why Millions Can’t Afford the Weight-Loss Drugs That Could Save Their Lives

A woman in her fifties recently spread her bills across the table and circled what could go in a peaceful kitchen outside of Dallas. a subscription to streaming services. A fresh phone plan. fewer meals at restaurants. She was attempting to hold onto her prescription for Zepbound, a drug that had helped her lose over 40 pounds and lower her blood pressure in a matter of weeks. It wouldn’t be covered by her insurance. The math was straightforward and harsh.

The medical discourse surrounding obesity has changed as a result of the new generation of weight-loss medications, such as Wegovy and Zepbound. Patients lost 15% to 25% of their body weight in clinical trials—numbers that were previously exclusive to bariatric surgery. Studies conducted more recently have revealed lower risks of stroke and heart attack. These medications might be prolonging lives rather than just reducing waist sizes.

Nevertheless, they continue to be unaffordable for millions of Americans. Without insurance, the sticker price may surpass $1,000 per month. For self-paying patients, the cost typically ranges from $300 to $500, despite recent price reductions by Novo Nordisk and Eli Lilly and Company. In theory, that might seem doable. It’s actually rent money. It’s groceries. The payment is for a car.

There’s a feeling that this instance highlights an unsettling aspect of American healthcare. Treatments that yield quantifiable, immediate returns within a single plan year are typically covered by insurers. But combating obesity takes time. The savings, which include fewer hospital stays, strokes, and amputations, frequently materialize years later, perhaps while a different insurer is in charge.

Medicare is still legally prohibited from paying for drugs prescribed only for weight loss. This ban began in 2003, when weight-loss medications were largely written off as cosmetic, and safety issues from past failures, such as fen-phen, persisted. Since then, the science has undergone significant change. The law hasn’t.

According to a 2024 study that was published in the Proceedings of the National Academy of Sciences, increased access to these drugs could prevent over 42,000 deaths in the US each year. It’s a startling, almost abstract figure. However, behind it are people balancing credit cards and prescription drugs while determining what to cut next.

A different type of frustration is described by doctors in a California bariatric clinic. When a patient’s body mass index falls below the qualifying threshold, coverage may be terminated if they lose 60 or 80 pounds while taking a GLP-1 medication. Whether insurers completely understand the biology at work is still up for debate. Weight gain is frequently the result of stopping these drugs. As one physician put it, telling a diabetic patient to stop taking insulin once their blood sugar stabilizes is similar to cutting someone off after they achieve success.

It is difficult to overlook the economic strain. It could cost tens of billions of dollars a year to cover even a small portion of eligible Medicare beneficiaries. An already vulnerable system is under stress, according to budget analysts. Meanwhile, economists contend that preventing diabetes and heart disease could save hundreds of billions over the course of ten years. Depending on the time period and underlying assumptions, either prediction may come to pass.

Last month, a man in his early sixties stood by the counter of a suburban pharmacy and asked quietly if there were any coupons that would lower the price of his refill. Coverage had been rejected by his plan. He was advised to start with older medications, which are known to have negative side effects and, at best, only slightly reduce weight. This type of “step therapy,” in which patients must first fail less expensive treatments in order to receive more advanced ones, has become widespread.

It’s possible that insurers are just protecting themselves from unpredictability. Since these medications are still relatively new, long-term safety information is still being gathered. Some health plans worry that demand will overwhelm them. Over 40% of adult Americans suffer from obesity. The cost increases rapidly if even a small percentage seek treatment.

However, as this develops, there’s a sense that stigma is still present in the discussion. It has long been claimed that willpower, not biology, is the cause of obesity. The unwillingness to pay implies that outdated beliefs still exist beneath the spreadsheets, despite the availability of efficient pharmaceutical tools.

In the meantime, pharmaceutical companies are experimenting with direct-to-consumer business models, cutting costs, and introducing online portals that circumvent conventional pharmacy benefit managers. Compared to traditional healthcare, the actions are more akin to retail competition. It’s unclear if this strategy reduces systemic costs or just moves them.

The calculus is instantaneous for patients. A drug that improves sleep apnea, lowers blood pressure, silences “food noise,” and lowers cardiovascular risk can feel life-changing. It can be unsettling to lose access. The weight slowly returns. The fears also do.

There is more to the insurance dispute over weight-loss medications than just money. It has to do with how society views illness, prevention, and accountability. It concerns whether short-term costs are justified by long-term health savings. It also concerns who will profit from one of the biggest developments in medicine in many years.

Millions of people wait with prescriptions in hand and calculators close by while legislators discuss coverage expansions and employers assess costs. Science is advancing swiftly. Less so is the insurance system. And lives are at stake somewhere between them.